Avapritinib for Cutaneous Mastocytosis
- PMID: 33241424
- PMCID: PMC9309867
- DOI: 10.2340/00015555-3709
Avapritinib for Cutaneous Mastocytosis
Figures



References
-
- Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, et al. . The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014; 93: 81–88. - PubMed
-
- Severino M, Chandesris MO, Barete S, Tournier E, Sans B, Laurent C, et al. . Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement. J Am Acad Dermatol 2016; 74: 885–891 e881. - PubMed
-
- Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, et al. . A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med 2017; 9: eaao1690. - PubMed
-
- Drummond MW, DeAngelo DJ, Deininger MW, Radia D, Quiery AT, Hexner EO, et al. . Preliminary safety and clinical activity in a Phase 1 study of Blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (SM). Blood 2016; 128: 477–477.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources